Zymeworks Inc. Common Stock (ZYME)

Zymeworks Inc. Common Stock (ZYME) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.9B; returns 1 day -0.8%, 1 week +12.7%, 1 year +62.1%.

Zymeworks Inc. is a clinical-stage biopharmaceutical company that has transitioned into a hybrid royalty-aggregator and R&D innovator model. Its business is built on two proprietary technology platforms: Azymetric, used for developing bispecific and multispecific antibodies, and a suite of Antibody-Drug Conjugate (ADC) technologies. Revenue is predominantly driven by milestone payments (approx.

Groups ZYME belongs to

• Shrinking Share Count
• Biotechnology
• Biopharmaceutical
• Clinical Stage
• Clinical Stage Biotech
• Oncology
• Antibody-Drug Conjugates
• Royalty Streams
• Bispecific Antibodies
• Antibody Therapeutics
• Healthcare
• Life Sciences
• Cancer Therapeutics
• R&D
• Monoclonal Antibodies

ZYME financial model: income statement, cash flow and balance sheet